EMA Authorised: Atriance (nelarabine) — Sandoz Pharmaceuticals d.d.

View source ↗

Summary

The European Medicines Agency authorized Atriance (nelarabine) for precursor T-cell lymphoblastic leukemia/lymphoma, with Sandoz Pharmaceuticals d.d. as the mar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Precursor T-cell Lymphoblastic Leukemia Lymphoma

Drugs mentioned

• Atriance (nelarabine)

Snippet

Status: Authorised. Therapeutic area: Precursor T-Cell Lymphoblastic Leukemia-Lymphoma. MAH: Sandoz Pharmaceuticals d.d.. Decision date: 16/04/2026